cardiometabolic conditions

Showing 1 posts of 1 posts found.

researchers_credit_neusentis_pfizer

Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025

May 12, 2025
Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …

The Gateway to Local Adoption Series

Latest content